This third course in the Biosimilars Continuing Education Series entitled "Biologic and Biosimilar Pharmacovigilance" will highlight the unique pharmacovigilance challenges that biosimilars pose and examine the various approaches regulators in the U.S. and elsewhere have implemented to address these challenges.

After completing this module, the participant should be able to:

1. Define pharmacovigilance
2. Explain the role of the FDA in relation to Biosimilars
3. Identify unique pharmacovigilance challenges biosimilars pose
4. Identify globally existing problems with pharmacovigilance programs
5. Recognize ways to address existing problems with pharmacovigilance programs

The College of Pharmacy at The Ohio State University is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program is approved for 1.0 contact hours (0.1 CEU) under the ACPE universal program number 0633-0000-22-021-H01-P. Participants must view the video, achieve an 80% on the quiz and complete the evaluation to receive CE credit for program. Questions about pharmacist's participation in the program and continuing education credit should be addressed to Brooke Keber at cop-cpd@osu.edu.